Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study

Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating clinicopathological features and inflammatory signature to predict LR in LARC patients undergoing neoadjuvant therapy followed by total mesorectal excision.

NCT Number	NCT07351708
Lead Sponsor	Cai Zerong
Conditions	Locally Advanced Rectal Cancer (LARC)
Enrollment	2,315 participants
Start Date	2010-01-06
Primary Completion	2022-12-30 (estimated)
Study Completion	2025-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-20